Drugs / BI 765080
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05075772 | Oct 2021 → Mar 2022 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04666922 | Jan → Aug 2021 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 765080 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04666922 ↗ |
| Route | Intravenous | “following intravenous administration of single rising doses” NCT04666922 ↗ |